Peptide Therapeutic Agent for Autoimmune and Inflammatory Disease - Genesen Co
Summary
The European Patent Office published patent application EP2024117293A1 for Genesen Co., Ltd., covering a peptide therapeutic agent for treating autoimmune and inflammatory diseases. The application, filed under IPC classifications C07K 7/08 and A61P 37/00/29/00, designates 32 European Contracting States. The patent publication marks completion of the EPO's formal publication requirements for the pharmaceutical peptide invention.
What changed
The EPO formally published patent application EP2024117293A1 for a peptide therapeutic agent developed by Genesen Co., Ltd. The application covers compositions and methods for treating autoimmune diseases (A61P 37/00) and inflammatory diseases (A61P 29/00) using peptide-based therapeutics classified under C07K 7/08.
Pharmaceutical companies developing competing autoimmune or inflammatory peptide therapies should conduct freedom-to-operate analyses and monitor the prosecution history. Research institutions may find the technical claims useful for landscape analysis. No immediate compliance obligations arise from this publication alone, but patent publication triggers the 9-month window for third-party observations under EPC Article 115.
What to do next
- Monitor EPO register for further examination progress
- Review patent claims for freedom-to-operate assessment
- Track international filing deadlines under PCT
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PEPTIDE THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE AND INFLAMMATORY DISEASE
Publication EP2024117293A1 Kind: A1 Apr 01, 2026
Applicants
Genesen Co., Ltd.
Inventors
The designation of the inventor has not yet been filed
IPC Classifications
C07K 7/08 20060101AFI20240607BHEP A61P 37/00 20060101ALI20240607BHEP A61P 29/00 20060101ALI20240607BHEP A61K 38/00 20060101ALI20240607BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.